CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Effect of Portulaca Oleracea (purslane) extract on liver enzymes, lipid profile, and glycemic status in nonalcoholic fatty liver disease: A randomized, double-blind clinical trial
Authors
M. Akbari-Fakhrabadi
R. Darvish Damavandi
+5 more
A. Dehnad
L. Janani
M. Masoodi
M. Najafi
F. Shidfar
Publication date
1 January 2021
Publisher
Abstract
Purslane (Portulaca oleracea L.) is the richest green leafy vegetable source of omega-3, especially alpha linolenic acid (ALA). Experimental studies have shown beneficial effects of purslane extract on liver enzymes. The aim of the present study was to examine the effect of purslane hydroalcohoic extract in patients with non-alcoholic fatty liver disease (NAFLD). In a randomized double-blinded clinical trial, 74 patients were randomly assigned to receive either 300 mg purslane extract or placebo capsules for 12 weeks. Compared with baseline, alanine aminotransferase (ALT) (�9 �17, 0.50 mg/dl; p =.007), aspartate aminotransferase (AST) (�4 �10, �0.50 mg/dl; p =.001), gamma glutamyltransferase (GGT) (�6.21 ± 9.85 mg/dL; p <.001), fasting blood glucose (FBG) (�8 �11, �1.50 mg/dl; p <.001) insulin resistance (�0.95 ± 2.23; p =.020), triglyceride (�20 �67.50, 3.50 mg/dl; p =.010), and low-density lipoprotein cholesterol (LDL-C) (�5 �12, �1 mg/dl; p <.001) decreased significantly in the purslane group. At the end of study, no significant changes were observed in liver steatosis grade, insulin, liver enzymes, total bilirubin, lipid profile, and blood pressure between the two groups. The findings of our study show that purslane extract at the dose of 300 mg/day for 12 weeks has no significant effects on liver enzymes, lipid profile, and glycemic indices in patients with NAFLD. © 2021 John Wiley & Sons, Ltd
Similar works
Full text
Available Versions
eprints Iran University of Medical Sciences
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:eprints.iums.ac.ir:39280
Last time updated on 17/12/2021